M. Blivet-Van Eggelpoël

Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma

C. Venot, C. Desbois-Mouthon, L. Fartoux, 2009, Clinical Cancer Research.

Insulin-mediated cell proliferation and survival involve inhibition of c-Jun N-terminal kinases through a phosphatidylinositol 3-kinase- and mitogen-activated protein kinase phosphatase-1-dependent pathway.

A. Atfi, F. Bertrand, C. Desbois-Mouthon, 2000, Endocrinology.

Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.

C. Desbois-Mouthon, V. Barbu, L. Fartoux, 2012, Journal of hepatology.

Glycogen synthase kinase-3 inhibitors augment TRAIL-induced apoptotic death in human hepatoma cells.

C. Desbois-Mouthon, S. Moritz, M. Kornprobst, 2009, Biochemical pharmacology.

GSK-3beta inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression.

C. Ruiz-Ruiz, C. Desbois-Mouthon, A. Cadoret, 2004, Experimental cell research.

Impact of IGF‐1R/EGFR cross‐talks on hepatoma cell sensitivity to gefitinib

Wulfran Cacheux, W. Cacheux, C. Desbois-Mouthon, 2006, International journal of cancer.

Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation.

F. Bertrand, C. Desbois-Mouthon, A. Cadoret, 2001, Oncogene.

Dysregulation of glycogen synthase kinase-3beta signaling in hepatocellular carcinoma cells.

C. Desbois-Mouthon, A. Cadoret, J. Capeau, 2002, Hepatology.